Abstract

BackgroundDespite the development of biomarkers and noninvasive imaging tools, biopsy remains the only method for correctly diagnosing patients with unexplained hematuria, proteinuria and renal failure. Renal biopsy has been performed for several decades in Taiwan; however, a national data registry is still lacking until 2013.MethodsThe Renal Biopsy Registry Committee was established within the Taiwan Society of Nephrology in January 2013. A biopsy registry format, including basic demographic data, baseline clinical features, laboratory data, and clinical and pathological diagnosis was developed. Approval from the local institutional review board was obtained in each participating medical center.ResultsFrom January 2014 to September 2016, 1445 renal biopsies were identified from 17 medical centers. 53.8% cases were reported in men. After excluding renal transplantation, renal biopsies were commonly performed in patients with primary glomerulonephritis (48.1%), secondary glomerulonephritis (36.2%), followed by tubulointerstitial diseases (12.3%) and vascular nephropathy (3.4%). Among primary glomerulonephritis, IgA nephropathy (26.0%), focal segmental glomerulosclerosis (21.6%), and membranous nephropathy (20.6%) were most frequently diagnosed. Diabetic nephropathy (22.4%) and lupus nephritis (21.8%) were the most common among secondary glomerulonephritis. Patients with minimal change disease and membranous nephropathy had heavier proteinuria than those with focal segmental glomerulosclerosis and IgA nephropathy (P < 0.001). Patients with minimal change disease had higher serum IgM and IgE levels. The most common cause of nephrotic syndrome in primary glomerular disease was membranous nephropathy (28.8%), followed by minimal change disease (28.2%). IgA nephropathy was the leading cause of chronic nephritic syndrome, acute nephritic syndrome, and persistent hematuria. The incidence of primary glomerulonephritis was approximately 2.19 in 100,000/year.ConclusionsThis is the first report of the National Renal Biopsy Registry in Taiwan. IgA nephropathy is the most common primary glomerulonephritis, while membranous nephropathy is the most common cause of nephrotic syndrome. Primary glomerulonephritis distribution in Taiwan is slightly different from that in other Asian countries.

Highlights

  • Despite the development of biomarkers and noninvasive imaging tools, biopsy remains the only method for correctly diagnosing patients with unexplained hematuria, proteinuria and renal failure

  • Renal biopsy remains a powerful tool for correctly diagnosing patients with unexplained hematuria, proteinuria and renal failure

  • Baseline clinical features were classified as follows: (1) acute nephritic syndrome, (2) rapidly progressive glomerulonephritis (RPGN), (3) persistent hematuria, (4) chronic nephritic syndrome, (5) nephrotic syndrome or unexplained proteinuria, (6) acute kidney injury, (7) drug-induced nephropathy, (8) kidney disease-associated vasculitis, (9) kidney disease associated with metabolic disorder, and (10) others

Read more

Summary

Introduction

Despite the development of biomarkers and noninvasive imaging tools, biopsy remains the only method for correctly diagnosing patients with unexplained hematuria, proteinuria and renal failure. Based on the United States Renal Data System (USRDS) report, Taiwan has the highest incidence and prevalence of end-stage renal disease (ESRD) [1]. DM and chronic GN are the leading cause of ESRD in Japan and China [3, 4]. DM and hypertension are the most common etiologies in all developed and many developing countries, whereas chronic GN is more common in Asian countries, such as China, Japan, and Taiwan [5]. Renal biopsy remains a powerful tool for correctly diagnosing patients with unexplained hematuria, proteinuria and renal failure. Renal biopsy has been performed for several decades in Taiwan; a national data registry is still lacking until 2013

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call